- Stocks
- Pharma & Healthcare
- Shilpa Medicare
Shilpa Medicare share price
NSE: SHILPAMEDPharma & HealthcareDrug Manufacturers - Specialty & Generic
Shilpa Medicare at a glance
Shilpa Medicare (NSE: SHILPAMED) closed at ₹880.90 on 22 Oct 2026, up 4.74% on the day. With a market capitalisation of ₹17,229 Cr, it ranks 382nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 70.9× trailing earnings, against a return on equity of 9.4% in FY26. Over the past year the share price has risen 150.3%. Its 52-week range is ₹259.50 (27 Jan 2026) to ₹1,095.00 (1 Oct 2026); the last close is 19.6% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹466 Cr (+44.9% year on year) and net profit ₹95 Cr (+99.3%), on a consolidated basis. Promoters held 40.13% of the company as of 30 Jun 2026; 8.73% of promoter shares were pledged.
Key numbers
- Market cap
- ₹17,229 CrRank 382 on NSE
- P/E (trailing)
- 70.9×
- Price to book
- 2.63×FY26
- EPS (TTM)
- ₹15.28to Q1 FY27
- ROE
- 9.4%FY26
- ROCE
- 11.4%FY26
- Debt to equity
- 0.25FY26
- Net profit margin
- 14.7%FY26
- Book value / share
- ₹132.47FY26
- 52-week high
- ₹1,095.001 Oct 2026
- 52-week low
- ₹259.5027 Jan 2026
- 1-year return
- +150.3%
- RSI (14-day)
- 39.5
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +4.74% | −8.6% | −17.5% | +43.9% | +150.3% |
Shilpa Medicare quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹344 Cr | ₹319 Cr | ₹331 Cr | ₹321 Cr | ₹370 Cr | ₹410 Cr | ₹437 Cr | ₹466 Cr |
| Revenue YoY | +9.8% | +11.5% | +13.4% | +9.9% | +7.6% | +28.3% | +32.1% | +44.9% |
| Net profit | ₹18 Cr | ₹31 Cr | ₹12 Cr | ₹48 Cr | ₹44 Cr | ₹45 Cr | ₹89 Cr | ₹95 Cr |
| Net profit YoY | +426.7% | +444.9% | −50.4% | +170.9% | +141.0% | +42.9% | +632.8% | +99.3% |
| Net margin | 5.3% | 9.8% | 3.7% | 14.8% | 11.9% | 11.0% | 20.5% | 20.4% |
| EPS | ₹1.83 | ₹3.25 | ₹1.48 | ₹4.79 | ₹2.25 | ₹2.36 | ₹5.51 | ₹5.16 |
Shilpa Medicare financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹901 Cr | ₹1,146 Cr | ₹1,050 Cr | ₹1,152 Cr | ₹1,286 Cr | — |
| Operating profit | ₹136 Cr | ₹97 Cr | −₹34 Cr | ₹53 Cr | ₹152 Cr | — |
| Net profit | ₹148 Cr | ₹64 Cr | −₹27 Cr | ₹37 Cr | ₹80 Cr | — |
| EPS (₹) | ₹18.00 | ₹7.00 | −₹4.00 | ₹4.00 | ₹8.00 | — |
| Cash from operations | ₹47 Cr | ₹105 Cr | ₹226 Cr | ₹135 Cr | ₹132 Cr | — |
| Total debt | ₹480 Cr | ₹354 Cr | ₹289 Cr | ₹560 Cr | ₹232 Cr | ₹184 Cr |
| Shareholders' equity | ₹1,479 Cr | ₹1,822 Cr | ₹1,783 Cr | ₹1,809 Cr | ₹2,372 Cr | ₹2,591 Cr |
Shilpa Medicare shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 44.23% | 44.23% | 44.23% | 40.13% | 40.13% | 40.13% |
| Foreign institutions | 10.97% | 11.20% | 10.92% | 10.97% | 11.08% | 11.38% |
| Domestic institutions | 7.55% | 7.46% | 7.67% | 8.33% | 8.58% | 8.05% |
| Non-institutions | 37.25% | 37.11% | 37.18% | 40.56% | 40.21% | 40.43% |
| Promoter shares pledged | 7.92% | 7.92% | 7.92% | 8.73% | 8.73% | 8.73% |
Shilpa Medicare vs peers
The listed Pharma & Healthcare companies nearest to Shilpa Medicare by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| IGLIndraprastha | ₹141.87 | −0.11% | −33.1% | ₹19,862 Cr | 12.8 | — |
| COHANCECohance Lifesciences | ₹460.30 | −0.25% | −46.9% | ₹17,610 Cr | 98.6 | — |
| SHILPAMEDShilpa Medicare | ₹880.90 | +4.74% | +150.3% | ₹17,229 Cr | 70.9 | — |
| PFIZERPfizer | ₹3,712.10 | −0.93% | −30.9% | ₹16,982 Cr | 23.5 | — |
| CAPLIPOINTCaplin Point Laboratories | ₹2,227.80 | +0.35% | +12.9% | ₹16,934 Cr | — | — |
| ERISEris Lifesciences | ₹1,143.60 | +0.76% | −27.9% | ₹15,848 Cr | 25.3 | — |
| ONESOURCEOnesource Specialty Pharma | ₹1,378.00 | +1.64% | −25.1% | ₹15,798 Cr | — | — |
Ask anything about Shilpa Medicare
Pivot answers on the live chart with evidence you can check, and tests strategies against SHILPAMED's own history. Try: “Why has SHILPAMED moved over the last three months?” · “Backtest a 50-day moving-average crossover on SHILPAMED over five years” · “Compare SHILPAMED with IGL on margins and valuation”
Frequently asked questions about Shilpa Medicare
What is the share price of Shilpa Medicare today?
Shilpa Medicare (NSE: SHILPAMED) last closed at ₹880.90 on 22 Oct 2026. Its 52-week high is ₹1,095.00 and its 52-week low is ₹259.50.
What is the market cap of Shilpa Medicare?
Shilpa Medicare's market capitalisation is ₹17,229 Cr (₹17,229 Cr) at the 22 Oct 2026 close, ranking 382nd among the NSE companies Pivot tracks.
What is the P/E ratio of Shilpa Medicare?
Shilpa Medicare trades at a trailing P/E of 70.9. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 25.3.
What is the ROE and ROCE of Shilpa Medicare?
Return on equity was 9.4% in FY26 and return on capital employed was 11.4% in FY26 (consolidated figures).
Is Shilpa Medicare a debt-free company?
No. Shilpa Medicare's debt-to-equity ratio was 0.25 in FY26, with total debt of ₹184 Cr.
What were Shilpa Medicare's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Shilpa Medicare reported revenue of ₹466 Cr, +44.9% year on year, and net profit of ₹95 Cr, +99.3% year on year.
How has Shilpa Medicare stock performed over the last year?
Shilpa Medicare's share price has risen 150.3% over the past year, +43.9% over three months and −17.5% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Shilpa Medicare?
As of 30 Jun 2026: promoters 40.13%, foreign institutions 11.38%, domestic institutions 8.05%, non-institutions 40.43%. 8.73% of promoter shares were pledged.
Who are Shilpa Medicare's competitors?
The listed Pharma & Healthcare companies closest to Shilpa Medicare by market cap are Indraprastha, Cohance Lifesciences, Pfizer, Caplin Point Laboratories, Eris Lifesciences and Onesource Specialty Pharma.
Is Shilpa Medicare a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Shilpa Medicare's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SHILPAMED against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text